MyPeBS en questions

Version française

A new example of semantic shift: from non-inferior to more beneficial.

16/08/2021 - The MGEN mutual insurance company invites its members to take part in MyPeBS through its website. Once again (see news of 19/07/21) MyPeBS is presented as a study aimed at demonstrating the superiority of an individualized screening over the current screening.     Read more



Semantic shift from non-inferior to possibly superior. A good example!

19/07/2021 - The insurance and pension fund (CPR SNCF) of the French National Railways (SNCF) sends an email to women insured inviting them to participate in the MyPeBS study. Although MyPeBS is a non-inferiority study, the letter states that « researchers will assess whether personalized screening would be more effective than the one currently organized. »     Read more



To inform or to promote, one has to choose. The INCa's conflict of interest.

28/06/2021 - The INCa openly expresses its determination to promote breast cancer screening at all costs, even if it means deliberately withholding information from women and censoring the media if they want to report on it.     Read more



Unacceptable, French National Institute of Cancer (INCa) wants to introduce censorship of information on cancers !

24/06/2021 - By qualifying as Fake news the doubts expressed regarding the benefits / risks balance of breast cancer screening, INCa is implementing the first act of a strategy that aims to censor sites of information on cancers.     Read more



« Is breast cancer screening useless or even harmful ? » : analysis of French National Cancer Institute (INCa) arguments

22/06/2021 - After a post denouncing the unacceptable conduct of INCa, which treats as Fake news any questioning on the interest of breast cancer screening, here is an analysis of the arguments used by INCa.     Read more



When INCa (National Institute of Cancer France) is losing its nerve

20/06/2021 - Willing to do whatever it takes to promote screening, the INCa has just crossed a red line by qualifying as fake-news the questioning of the benefit/risk balance in breast cancer screening.     Read more



Dernière mise à jour le 06/10/2021